Sean M. Healey & AMG Center for ALS Announces the Names of 54 Selected Sites for the HEALEY ALS Platform Trial

The Sean M. Healey & AMG Center at Massachusetts General Hospital, in collaboration with the Northeast ALS Consortium (NEALS), is launching the first platform trial for amyotrophic lateral sclerosis (ALS). The goals of this groundbreaking project are to greatly accelerate the timelines towards effective ALS treatments and provide greater trial access for all those affected by this disease. Visit the trial page on ClinicalTrials.gov for more information about sites and trial participation criteria.

The HEALEY ALS Platform Trial is a collaborative effort and enrollment in the trial will be available at several sites across the U.S. to bring the trial close to people who want to participate. All sites are part of the NEALS Consortium. See below for a list of participating sites.

For more information, please email HEALEYALSPlatform@mgh.harvard.edu.

Map of Participating Sites

List of Participating Sites by State

Site

State

Contact Information

Barrow Neurological Institute

Arizona

Jessie Duncan

Forbes Norris MDA/ALS Research Center, California Pacific Medical Center

California

Marguerite Engel

University of California, Irvine

California

Vivian Li

Cedars-Sinai Medical Center

California

Carolyn Prina

Loma Linda University Health

California

Blanca Herrera

University of Colorado Anschutz

Colorado

Brianna Blume

Hospital for Special Care

Connecticut

Natalie Schmitt

Phil Smith Neuroscience Institute at Holy Cross Hospital

Florida

Donovan Mott

Mayo Clinic Florida

Florida

Lisa Thuro

University of Florida Gainesville

Florida

Jennifer Steshyn

University of Miami

Florida

Wendy Levy

University of South Florida College of Medicine

Florida

Jessica Shaw

Emory University

Georgia

Meraida Polak

University of Chicago

Illinois

Shail Bhatnagar

Northwestern University

Illinois

Ben Joslin

University of Iowa Hospitals and Clinics

Iowa

Jeri Sieren

University of Kansas Medical Center

Kansas

Andrew Heim

University of Kentucky

Kentucky

Meg Bruno

Ochsner Health Systems

Louisiana

Kristina Brown

Johns Hopkins University

Maryland

Kristen Riley

University of Maryland

Maryland

Vikram Nambiar

Beth Israel Deaconess Medical Center

Massachusetts

Hilda Guitierrez

Massachusetts General Hospital

Massachusetts

Danny Hevert

University of Massachusetts Medical School, Worcester

Massachusetts

Diane McKenna-Yasek

Henry Ford Health System

Michigan

Anne Vallis

University of Michigan

Michigan

Jayna Duell

Spectrum Health

Michigan

Nichole Roderique

Mayo Clinic Rochester

Minnesota

Carol Denny

University of Minnesota/Twin Cities ALS Research Consortium

Minnesota

Valerie Ferment

University of Missouri Health Care

Missouri

Natalie Taylor

Saint Louis University

Missouri

Susan Brown

Washington University School of Medicine

Missouri

Elizabeth Karanja

University of Nebraska Medical Center

Nebraska

Renee Hogue

Neurology Associates, P.C./Somnos Clinical Research

Nebraska

Desirae Eschiti

Dartmouth-Hitchcock Medical Center

New Hampshire

Caren Saunders

Columbia University

New York

Jessica Singleton

SUNY Upstate

New York

Jacob Pusey

Duke University

North Carolina

Lisa Harrison

Wake Forest University Health Sciences

North Carolina

Mozhdeh Marandi

The Ohio State University

Ohio

Erin Cohen

Providence Brain and Spine Institute ALS Center

Oregon

Arlena Cummings

University of Pennsylvania

Pennsylvania

Adreeja Guharay

Lewis Katz School of Medicine at Temple University

Pennsylvania

Kathleen Hatala

Jefferson Weinberg ALS Center, Thomas Jefferson University

Pennsylvania

Laura Oakley

Penn State Hershey

Pennsylvania

Anne Haulman

Medical University of South Carolina

South Carolina

Katrina Madden

Vanderbilt University Medical Center

Tennessee

Diana Davis

Wesley Neurology Clinic

Tennessee

Cindy Benzel

University of Texas Health Science Center at San Antonio (UTHSCSA)

Texas

Pamela Kittrell

Houston Methodist

Texas

Sharon Halton

Texas Neurology

Texas

Todd Morgan

University of Virginia

Virginia

Mary Wagoner

University of Washington

Washington

Laura Sissons-Ross

Medical College of Wisconsin

Wisconsin

Marie Mejaki

HEALEY ALS Platform Trial Indirect Cost Policy

In executing the Master Clinical Trial Agreement (MCTA) to participate in the HEALEY ALS Platform Trial, Sites agree they will be paid indirect costs (IDC) at the rate at which the originating funding organization reimburses MGH. For payments made from internal MGH philanthropic funds, the IDC will be capped at 15% of total direct costs.